CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and…
CytoDyn Inc. a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced it has executed an…
Read More...
Read More...
